Usted buscó: mcyr (Danés - Inglés)

opretholdt mcyr
maintained mcyr

mcyr (95% ki)
mcyr (95% ci)

”major” (mcyr) a
major (mcyr) a

cytogenetisk respons (%) mcyr
cytogenetic response (%) mcyr

resistent intolerant uden mcyr
medianresistant intolerant without mcyr time of imatinib treatment in

cytogent respons (%) mcyr alle patienter
cytogenetic response (%) mcyr all patients

det primære endpoint var mcyr ved 12 uger.
the primary endpoint was mcyr at 12 weeks.

opnåede mcyr på 45 mg (n=87)
achieved mcyr at 45 mg (n=87)

median varighed af mcyr var 32,7 måneder.
median duration of mcyr was 32.7 months.

[83% - 93%]) opretholdt mcyr i to år.
[83%-93%]) maintained mcyr for 2 years.

mcyr-raten hos 321 cp-patienter var 51 %.
the mcyr rate in 321 cp patients was 51%.

mcyr (0% ­35%) kombinerer komplette og delvise respons.
mcyr (0%­35%) combines both complete and partial responses.

andre sekundære endepunkt omfattede varighed af mcyr, pfs samt overordnet overlevelse.
other secondary endpoints included duration of mcyr, pfs, and overall survival.

mcyr (0% – 35%) kombinerer komplette og delvise respons.
mcyr (0% – 35%) combines both complete and partial responses.

andre sekundære endpoint omfattede varighed af mcyr, progressionsfri overlevelse samt overordnet overlevelse.
other secondary endpoints included duration of mcyr, progression-free survival, and overall survival.

varighed af mcyr, progressionsfri overlevelse og overordnet overlevelse var ensartet på tværs af de 4 behandlingsgrupper.
durations of mcyr, progression-free survival, and overall survival were similar across the four treatment groups.

mcyr- raten var 27% med en gennemsnitlig tid til respons på 2, 0 måneder.
the mcyr rate was 27% with a median time to response of 2.0 months.

det vigtigste sekundære endpoint var mcyr i forhold til total daglig dosis hos imatinib - resistente patienter.
the main secondary endpoint was mcyr by total daily dose level in the imatinib-resistant patients.

større cytogenetisk respons mcyr (0% ­35%) er kombinationen af fuldstændigt og delvist respons.
major cytogenetic response (mcyr) (0%­35%) combines both complete and partial responses.

de fleste af disse hændelser forekom med den dosis, hvor patienten opnåede mcyr; færre hændelser forekom efter dosisreduktion.
most of these events occurred at the dose at which the patient achieved mcyr; fewer events occurred after dose reduction.